Between the Biotech Waves

EXPLORE

Society & Culture

Health & Fitness

© 2024 PodJoint

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/e9/2c/28/e92c28b0-b01c-8abd-50e2-5b8751cf2e95/mza_12243287049817607168.jpg/600x600bb.jpg

Between the Biotech Waves

Nessan Bermingham PhD

43 episodes

6 months ago

Today’s episode features a remarkable leader in the field of gene therapy, Dr. Bobby Gaspar. With over 25 years of experience as a physician and scientist, Bobby has played a pivotal role in redefining treatment options for severe genetic disorders. As the co-founder and current CEO of Orchard Therapeutics, recently acquired by Kyowa Kirin, Bobby has been at the forefront of advancing gene therapy, particularly in hematopoietic stem cell gene therapy. His groundbreaking work includes some of ...

Show more...

All content for Between the Biotech Waves is the property of Nessan Bermingham PhD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Today’s episode features a remarkable leader in the field of gene therapy, Dr. Bobby Gaspar. With over 25 years of experience as a physician and scientist, Bobby has played a pivotal role in redefining treatment options for severe genetic disorders. As the co-founder and current CEO of Orchard Therapeutics, recently acquired by Kyowa Kirin, Bobby has been at the forefront of advancing gene therapy, particularly in hematopoietic stem cell gene therapy. His groundbreaking work includes some of ...

Show more...

Episodes (20/43)

Between the Biotech Waves

S2 E7: A Between the Biotech Waves Conversation with Bobby Gaspar

Today’s episode features a remarkable leader in the field of gene therapy, Dr. Bobby Gaspar. With over 25 years of experience as a physician and scientist, Bobby has played a pivotal role in redefining treatment options for severe genetic disorders. As the co-founder and current CEO of Orchard Therapeutics, recently acquired by Kyowa Kirin, Bobby has been at the forefront of advancing gene therapy, particularly in hematopoietic stem cell gene therapy. His groundbreaking work includes some of ...

6 months ago

58 minutes

Between the Biotech Waves

S2 E6: A Between the Biotech Waves Conversation with Steve Paul

I am thrilled to welcome Steve Paul to Between the Biotech Waves. With nearly 50 years of experience as a physician-scientist, Steve has made significant contributions to the fields of neuroscience, molecular neuropharmacology, and CNS drug discovery and development. He is the scientific co-founder of Sage Therapeutics, where he played a key role as the interim head of Research and Development during its formative stages which ultimately led to the approval of the first drug for postpartum de...

6 months ago

56 minutes

Between the Biotech Waves

S2 E5: A Between the Biotech Waves Conversation with Kent Rogers

Today, I are excited to welcome Kent Rogers, the Chief Executive Officer of EveryONE Medicines. Kent brings a wealth of experience to his new role, having held executive leadership positions at renowned pharmaceutical companies as well as emerging biotech firms. With over 30 years of expertise in brand and generic pharmaceuticals, specialty pharmacy, and healthcare supply chain management, Kent has been at the forefront of developing disruptive solutions that enhance access to new medicines t...

6 months ago

1 hour 1 minute

Between the Biotech Waves

Between the Biotech Waves - Sound Bite - Bill Hicks Co-Chair Life Sciences Practice Mintz

Sound Bite with Bill Hicks looking at the market and financing in real time.

6 months ago

22 minutes

Between the Biotech Waves

Between the Biotech Waves - Sound Bite - Paul Matteis Equity Analyst Stifel

Welcome to a Between the Biotech Waves sound bite, a short podcast to provide insight into the rapidly changing biotech environment - I am pleased to welcome Paul Matteis Managing Director, Head of Therapeutics Equity Research in Biotech at Stifel to discuss the current market dynamics affecting our biotech industry. RECORDED April 7th 2025

6 months ago

26 minutes

Between the Biotech Waves

S2 E4: A Between the Biotech Waves Conversation with Dan Lynch

In this episode, I am thrilled to welcome Dan Lynch, an Executive Venture Partner at Google Ventures and a seasoned leader in the biotechnology sector. Since joining GV in 2021, Dan has partnered with life sciences CEOs and executives, providing invaluable guidance as a trusted advisor and coach. His commitment to fostering long-term relationships underscores his belief that collaboration is essential in an industry filled with talented people. Dan brings a wealth of experience, having worked...

8 months ago

1 hour 1 minute

Between the Biotech Waves

S2 E3: A Between The Biotech Waves Conversation with Stan Crooke, Ionis & N-Lorem Founder

In today's episode, I am honored to welcome Stanley Crooke, the founder and CEO of Ionis Pharmaceuticals the first and leading antisense oligonucleotide biotech and founder, CEO and Chair of N-Lorem, a not for profit entity developing ASOs for ultra rare diseases. Stan is THE pioneer in the field of antisense oligonucleotide based RNA-targeted therapies. With a deep passion for science and innovation, Stan has dedicated his career to transforming the landscape of drug discovery and developmen...

8 months ago

1 hour 4 minutes

Between the Biotech Waves

S2 E2: A Between the Biotech Waves Conversation with Peter Barrett

Welcome to ‘Between the Biotech Waves,’ the podcast where we navigate the dynamic world of biotechnology and explore the minds driving its innovation. I’m your host, Nessan Bermingham, and today, we have a true visionary in the field, Peter Barrett. Peter is a partner at Atlas Venture, where he has been a key player in the creation of numerous novel therapeutic and drug discovery platform companies. With an unyielding passion for advancing healthcare, Peter has been directly involved in co-fo...

9 months ago

53 minutes

Between the Biotech Waves

S2 Episode 1: A conversation with Matt Porteus

Now that JPM '25 is behind us, where the weather was great but the mood was somber, back to podcasting!Welcome back to 'Between the Biotech Waves,' the podcast where we explore the frontiers of biotechnology and the remarkable individuals driving innovation. I’m your host, Nessan Bermingham, and today, we are honored to have Dr. Matt Porteus with us, a true pioneer in the field of genome editing.Dr. Porteus is making headlines for his role in the development of Lyfgenia, the groundbreaking CR...

9 months ago

54 minutes

Between the Biotech Waves

Episode 35: A Between the Biotech Waves Conversation with Mike Curtis, President & CEO of eGenesis

Welcome back to Between the Biotech Waves. I am sorry for the lack of episodes over the past few months, unfortunately life threw me a curve ball that I have been taking care of but now back and ready to go!Today it gives me great pleasure to introduce Mike Curtis, President and CEO of eGenesis. You may recall seeing eGenesis on the front cover of the New York Times recently following the first successful xenotransplantation of a genetically modified porcine kidney. This followed years of wor...

1 year ago

1 hour 5 minutes

Between the Biotech Waves

Episode 32: The Triplet Therapeutics story, from concept to birth, life & death.

Today we have an unusual (& long) podcast where we talk to key members of the Triplet Therapeutics management team. Triplet was founded to develop antisense oligonucleotides targeting the DNA damage response pathway that has been implicated in driving repeat disorders including Huntington's disease - the lead indication for Triplet. The team discusses the challenges in building the company and what ultimately led to it's demise.

2 years ago

1 hour 45 minutes

Between the Biotech Waves

Episode 33: A Between the Biotech Waves conversation with Eliot Forster, xCEO of F-star Therapeutics

Today I am talking to Eliot Forster xCEO of F-star Therapeutics.Eliot was at helm of the company as they reversed merged into Springbank Pharmaceuticals & through the recently announced acquisition by Sino Biopharma, a transaction that generated a lot of interest given the very public interactions with CFIUS.Prior to F-star, Eliot was CEO of Immunocore, Creabilis and Solace Pharmaceuticals following his multiple roles at Pfizer which included head of development and operations, European U...

2 years ago

1 hour 4 minutes

Between the Biotech Waves

Episode 30: A Between the Biotech Waves conversation with Barry Greene, CEO of Sage Therapeutics

Today we are talking to Barry Greene, CEO of Sage Therapeutics. Barry has had an amazing career spanning over 30 years in the biotech industry. Prior to Sage Barry was President of Alnylam shepherding it with John through its evolution from basic science through commercial product launch. Prior to ALNY Barry was general manager of Oncology at Millennium where he was directly involved in the approval and launch of Velcade. He is currently a member of the board of the Pharmaceutical Research an...

2 years ago

45 minutes

Between the Biotech Waves

Episode 31: A Between the Biotech Waves Conversation with Tim Yu

Today we are talking to Tim Yu. Tim is attending physician at the division of genetics and genomics at Boston Children’s Hospital and assoc prof of Pediatrics at Harvard Medical School. The scope of work that Tim does is well beyond what can be covered in this intro however I have gotten to know Tim through his leading the emerging filed of N of 1 plus drugs. Tim worked with Julia Vitarello to develop Milasen leading the way in truly personalized therapeutics. Please join me in welcoming Tim...

2 years ago

55 minutes

Between the Biotech Waves

Episode 29: A Between the Biotech Waves conversation with Joel Marcus, Founder & Exec Chair of Alexandria Real Estate

Today we are talking to Joel Marcus. He has shaped the life sciences industry through ARE from the buildings we use to venture and fund investing. His impact can be directly seen in major cities across the US from Boston to NY to San Francisco with over 22million sq ft of space. Beyond Alexandria he is a philanthropist who supports veterans and their families, and through his initiatives people suffering from the opioid crisis, homelessness and mental illness. Please join me in welcoming Joel.

2 years ago

53 minutes

Between the Biotech Waves

Episode 28 A Between the Biotech Waves Conversation with Rachel Meyers

Today we are talking to Rachel Meyers. Rachel was most recently the CSO of Faze Medicines a company she launched with TRV to focus on the regulation of biomolecular condensates to treat disease. Prior to Faze she was an EIR at TRV prior to which she spent nearly 2 decades at Alnylam. I have had the pleasure of working with Rachel getting an appreciation not only of her as a scientist, entrepreneur and operator but also her pure love of science, focus on company culture and her passion for div...

2 years ago

57 minutes

Between the Biotech Waves

Episode 27 A Between the Biotech Waves Conversation with Aoife Brennan, CEO of Synlogic

Today we are talking to Aofie Brennan, president and CEO of Synlogic. Aoife was trained as a doctor at Trinity College Dublin following which she moved to the US. After completing her postdoctoral research at Beth Israel Aofie joined TolerX focused on developing autoimmune therapies for type I diabetes. Following which Aoife spent 6 years at Biogen ultimately becoming head of Rare Disease Innovation, she was involved in the development of Spinraza, Alprolix and Eloctate. Aoife moved from Biog...

2 years ago

1 hour 6 minutes

Between the Biotech Waves

Episode 26: A Between the Biotech Waves conversation with Drew Weissman

Today we are talking to Drew Weissman. Drew is the Roberts Family Professor in Vaccine Research at Perelman School of Medicine and Director of the Penn Institute for RNA Innovation at the University of Pennsylvania. Drew has spent his career working on RNA biology and vaccine development. He, along with his colleague Katalin Kariko, have been pivotal in the development of mRNA vaccines most notably the COVID-19 vaccines developed by BioNTech/Pfizer and Moderna. Drew received his MD/PhD f...

2 years ago

57 minutes

Between the Biotech Waves

Episode 25: A Between the Biotech Waves conversation with Rodolphe Barrangou, the Todd R Klaenhammer Distinguished Professor at NC State University.

Today we are talking to Rodolphe Barrangou. Rodolphe is the Todd R Klaenhammer Distinguished Professor at NC State University. He is a scientist entrepreneur who has co-founded a multitude of biotech companies around CRISPR based approaches including CRISPR Biotechnologies, Ancilia Biosciences, TreeCo and Intellia Therapeutics. He is one of the pioneers in CRISPR-Cas9 dating back to his time as R&D director of genomics at DuPont. In 2007 Rodolphe was the lead author on a Science paper dem...

2 years ago

1 hour

Between the Biotech Waves

Episode 24: A Between the Biotech Waves conversation with John Hoffman, managing director & head of healthcare equity capital markets at Credit Suisse

I am delighted to welcome back John Hoffman to Between the Biotech Waves. John is managing director & head of healthcare equity capital markets at Credit Suisse. In mid 2022 John joined the podcast to discuss the market outlook for ’22 and many of his predictions were spot on. It was also one of the most downloaded podcasts of the year. I am welcoming him back to review ’22, lessons learned and crystal ball gaze into ’23. What are we seeing overall in the capital markets, is M&A now o...

2 years ago

51 minutes